Insulin degludec news archive
Take a look back at Novo Nordisk company announcements and press releases on developments for insulin degludec and insulin degludec / insulin aspart.
Insulin degludec is an ultra-long-acting basal insulin being developed by Novo Nordisk. Insulin degludec and insulin degludec / insulin aspart have been submitted to regulatory authorities for review but have not yet been approved for use.
APROM ID# 4045. Date of Approval: May 2012